Bristol Myers Squibb Receives Positive Chmp Opinion for Repotrectinib for the Treatment of Advanced Ros1-Positive Non-Small Cell Lung Cancer and Advanced Ntrk-Positive Solid Tumors
Bristol Myers Squibb獲得愛文思控股對Repotrectinib用於治療愛文思控股基因陽性的非小細胞肺癌和愛文思控股基因陽性實體腫瘤的積極Chmp意見
